Safety and Effectiveness Evaluation of iCover Covered Stent for the Treatment of the Aorto-iliac Occlusive Disease

Inclusion criteria 1. ≥ 18 years of age 2. Rutherford clinical stage 2 to 5 3. Significant (≥70%) stenosis of atheromatous iliac lesions evidenced by duplex scan, MRI CT angiography or arteriography 4. De novo atheromatous lesion of the aortoiliac segment 5. Patient informed about the study and collection of the patient's informed consent agreement Exclusion criteria Subjects will not be eligible to participate in the study if any of the following conditions are present in the subject: 1. Protected adult patients, guardianship, curatorship, safeguard of justice 2. Woman with possibility of pregnancy 3. Patient with asymptomatic atheromatous lesions 4. Patient with inflow lesion in the infrarenal aorta 5. Patient treated with Covered endovascular reconstruction of aortic bifurcation (CERAB reconstruction) 6. Acute ischemia or acute thrombosis 7. Non-atherosclerotic disease 8. History of coagulopathy 9. Severe comorbidities with life expectancy \<2 years 10. Contraindication to taking antiplatelet aggregation therapy (aspirin or clopidogrel). The patient must be able to take an antiplatelet aggregation for at least 3 months after the procedure 11. Patient participating in another clinical study which may interfere with the results 12. Comorbidity or any reason which, according to the investigator, could limit the participation, the patient's adherence with the follow-up or the scientific integrity of the study 13. Lesion near or adjacent to an aneurysm 14. Inability to follow-up during the investigation 15. Patient objection to participate in the investigation